Headache and Migraine

Investigators found that zonisamide was associated with a reduction in monthly migraine days for pediatric populations.

Meloxicam and rizatriptan (Symbravo, formerly AXS-07) is a CGRP medication approved for the acute treatment of migraine with or without aura.

Axsome Therapeutics expects the therapy to be commercially available in the United States in approximately 4 months.

The calcitonin gene-related peptide monoclonal antibody significantly reduced the number of monthly migraine days.

No medications were associated with improved quality of life or reduced headache duration.

New research presented at AMCP Nexus 2024 highlighted the effectiveness and cost-effectiveness of various migraine treatments, including onabotulinumtoxinA and fremanezumab, as well as the importance of migraine education programs for improving patient outcomes.

Patients with chronic migraine can frequently overuse acute medications, leading to medication overuse headaches.

Whereby gastroparesis can hinder the absorption of oral medications in the stomach, Tonix Pharmaceuticals is promoting alternative migraine treatments that bypass the digestive system.

Click Therapeutics announced that CT-132 met its primary endpoint in the phase 3 ReMMi-D trial.

Dive in and learn more about the answers to yesterday’s quiz.

Test your knowledge of migraine therapies.

Dive in and learn more about the answers to yesterday’s quiz.

For Migraine and Headache Awareness Month, Drug Topics spoke with Shivang Joshi, MD, MPH, RPh, FAHS to debunk migraine myths and explore resources to promote migraine awareness and education.

Test your knowledge of different migraine triggers.

A poster presented at AHS 2024 found that older patients tended to have more vitamin deficiencies compared to younger patients.

Dive in and learn more about the answers to yesterday’s quiz.

Test your knowledge different headache types.

Check out this list of resources to share with patients who are managing a migraine or other headache diagnosis.

These populations are also more likely to receive opioid analgesic therapies.

Although there were some differences in response after dosing, both OTC and oral prescriptions demonstrated statistically significant improvements in pain.

Zavegepant (Zavzpret) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray approved by the FDA for acute migraine treatment in adults.

Zavegepant joins other CGRP antagonists as an option for individuals experiencing migraine.

Study results add to the body of evidence demonstrating the efficacy of CGRP inhibitors for migraine treatment and prophylaxis.

Patients using the treatment reported reduced headache intensity and better quality of life.

Only the 60 mg dose of atogepant is approved for chronic migraine prevention.

Vitamin D supplementation may be an effective and safe adjunctive prophylactic therapy to topiramate for children who experience migraine attacks, showed a study conducted in Saudi Arabia.

The spray, called Zavzpret, intends to help individuals who struggle with migraines but can't take oral medication because of nausea or vomiting

Nerivio received clearance in January 2021 for use in acute migraine.

Nearly 40 million people in the United States suffer from migraine, with the World Health Organization classifying migraine as 1 of the 10 most disabling medical illnesses.